Groups

Research Focus

Former Employee. Nursing; Per Diem RN

Recent additions – View all

1. Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)

   Meeting Abstract

   Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
   Journal of Clinical Oncology (2017)

   Fulltext@MSK | Save
2. AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy

   Meeting Abstract

   Scher, H. I.; Graf, R.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Jendrisak, A.; Greene, S.; Rodriguez, A.; Dugan, L.; more...
   Journal of Clinical Oncology (2016)

   Fulltext@MSK | Save
3. Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients

   Meeting Abstract

   Scher, H. I.; Graf, R.; Louw, J.; Jendrisak, A.; Johnson, A.; Greene, S.; Rodriguez, A.; Schreiber, N. A.; McLaughlin, B.; Dugan, L.; more...
   Journal of Clinical Oncology (2016)

   Fulltext@MSK | Save